[Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder
E
E
III. Medizinische Universitätsklinik Mannheim, Universität Heidelberg. eva.lengfelder@med3.ma.uni-heidelberg.de
Schultheis
B
B
Büchner
T
T
Hehlmann
R
R
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017209:Apoptosis; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004357:Drug Synergism; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D010087:Oxides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D012307:Risk Factors; D013997:Time Factors
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide